The antioxidant MnTBAP does not effectively downregulate CD4 expression in T cells in vivo

Area of Science:

• Immunology
• Pharmacology

Background:

• The antioxidant MnTBAP was previously observed to reduce CD4 molecule surface expression on T cells.
• This effect holds potential for treating human autoimmune diseases.

Purpose of the Study:

• To investigate the in vivo efficacy of MnTBAP in downregulating CD4 expression in T cells.
• To assess the impact of MnTBAP on experimental autoimmune encephalomyelitis (EAE) in mice.

Main Methods:

• C57BL/6 mice were actively immunized for EAE.
• Mice received single doses of MnTBAP or a vehicle control.
• Flow cytometry was used to analyze CD4 expression (frequency and MFI) on T cells.
• Survival rates were monitored in treated and control groups.

Main Results:

• In vivo administration of MnTBAP did not alter the mean frequency or median fluorescent intensity (MFI) of CD4+ T cells compared to vehicle controls.
• MnTBAP treatment resulted in a significantly shorter survival time in EAE mice (16.6 days) compared to controls (23.6 days).

Conclusions:

• MnTBAP is ineffective at downregulating T cell CD4 expression in vivo, likely due to mechanisms distinct from in vitro models.
• Potential toxicity and limited central nervous system (CNS) availability may restrict MnTBAP's clinical application for immunomodulation via CD4 downregulation.